MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Vericel Corporation Accounts Receivables 2011-2026 | VCEL
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Vericel Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 84.6 M | 61.4 M | 58.4 M | 46.5 M | 37.4 M | 34.5 M | 32.2 M | 23.5 M | 18.3 M | 17.1 M | 10.9 M | 8.19 M | - | - | 9 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 84.6 M | 9 K | 33.3 M |
Quarterly Accounts Receivables Vericel Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60.4 M | 64.3 M | 52.9 M | 61.4 M | 48.5 M | 48 M | 49.9 M | 58.4 M | 39.7 M | 38.3 M | 38.4 M | 46.5 M | 34.3 M | - | 31.9 M | 37.4 M | 28.9 M | 31.7 M | 29.1 M | 34.5 M | 34.5 M | 34.5 M | 34.5 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 10.9 M | 10.9 M | 10.9 M | 10.9 M | 8.19 M | 8.19 M | 8.19 M | 8.19 M | 8 K | 8 K | 8 K | - | 28 K | 9 K | 9 K | 11 K | 9 K | 9 K | 9 K | 9 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 64.3 M | 8 K | 24.2 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K |  USA |
 |
ADMA Biologics
ADMA
|
158 M | $ 16.45 | 0.43 % | $ 3.92 B | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 3.64 | -1.89 % | $ 1.09 B |  Canada |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
Aptorum Group Limited
APM
|
62.2 K | $ 0.83 | 4.23 % | $ 4.53 M | China |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
222 M | $ 76.75 | 0.85 % | $ 1.48 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
366 M | $ 19.93 | -1.14 % | $ 2.51 B | USA |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
Athersys
ATHX
|
739 K | - | 3.77 % | $ 22.4 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
9.81 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
224 M | $ 163.82 | -0.14 % | $ 8.15 B | USA |
 |
BridgeBio Pharma
BBIO
|
139 M | $ 66.98 | 3.8 % | $ 12.8 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
312 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
56.9 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
865 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
205 K | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
18.5 M | - | -7.31 % | $ 87 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
908 M | $ 60.75 | 3.79 % | $ 11.7 B | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
800 K | $ 3.24 | 1.73 % | $ 1.16 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Agios Pharmaceuticals
AGIO
|
3.43 M | $ 28.49 | 0.04 % | $ 1.65 B | USA |
 |
CymaBay Therapeutics
CBAY
|
277 K | - | - | $ 3.45 B | USA |
 |
Avid Bioservices
CDMO
|
16.6 M | - | - | $ 789 M | USA |